These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34958422)

  • 1. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
    Hribernik N; Huff DT; Studen A; Zevnik K; Klaneček Ž; Emamekhoo H; Škalic K; Jeraj R; Reberšek M
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1857-1869. PubMed ID: 34958422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients: a prospective study.
    Hribernik N; Strasek K; Huff DT; Studen A; Zevnik K; Skalic K; Jeraj R; Rebersek M
    Radiol Oncol; 2024 Sep; 58(3):335-347. PubMed ID: 39287171
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Nienhuis PH; Antunes IF; Glaudemans AWJM; Jalving M; Leung D; Noordzij W; Slart RHJA; de Vries EFJ; Hospers GAP
    J Nucl Med; 2022 Jun; 63(6):899-905. PubMed ID: 34503964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organ-specific accuracy of [
    Gideonse BM; Birkeland M; Vilstrup MH; Grupe P; Naghavi-Behzad M; Ruhlmann CH; Gerke O; Hildebrandt MG
    Jpn J Radiol; 2024 Jul; 42(7):753-764. PubMed ID: 38504000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Image intensity histograms as imaging biomarkers: application to immune-related colitis.
    Huff DT; Ferjancic P; Namías M; Emamekhoo H; Perlman SB; Jeraj R
    Biomed Phys Eng Express; 2021 Sep; 7(6):. PubMed ID: 34534974
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessing immune organs on
    Prigent K; Lasnon C; Ezine E; Janson M; Coudrais N; Joly E; Césaire L; Stefan A; Depontville M; Aide N
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2573-2585. PubMed ID: 33432374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
    Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
    Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
    Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
    Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
    Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related [
    Santo G; Cucè M; Restuccia A; Del Giudice T; Tassone P; Cicone F; Tagliaferri P; Cascini GL
    Cancer Imaging; 2024 Sep; 24(1):125. PubMed ID: 39289716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
    Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
    PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
    Wachsmann JW; Ganti R; Peng F
    Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
    Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S
    Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
    Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral
    Ma Y; Zeng J; Ding F; Xu Y; Wang Y; Zhong G; Liu N; Wang Y; Li Y; Chen S; Wei X; Zhu P; Jian G; Niu YS; Fu G; Liu C; Li G; Zhou X; Zhang A; Weng S
    J Nucl Med; 2024 Jul; 65(7):1129-1136. PubMed ID: 38697671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of preoperative (18)F-FDG PET-CT in lymphatic metastasis diagnosis of cutaneous malignant melanoma on extremities and trunk].
    Zhang XX; Fang Y; Xu LB; Xu SF; Zhao ZG; Sun C; Ma PQ; Liu T; Yu SJ; Zhang WJ
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):372-378. PubMed ID: 29860765
    [No Abstract]   [Full Text] [Related]  

  • 17.
    Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
    J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma.
    Ferdinandus J; Zaremba A; Zimmer L; Umutlu L; Seifert R; Barbato F; Ugurel S; Chorti E; Grünwald V; Herrmann K; Schadendorf D; Fendler WP; Livingstone E
    Cancer Imaging; 2022 Feb; 22(1):11. PubMed ID: 35123578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
    Nobashi T; Baratto L; Reddy SA; Srinivas S; Toriihara A; Hatami N; Yohannan TK; Mittra E
    Clin Nucl Med; 2019 Apr; 44(4):e272-e279. PubMed ID: 30688730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.